Canon Medical Signals Its Support for a Multicenter Ultrasound Liver Evaluation and Assessment Study

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Canon Medical announced today its support for the iLEAD (innovative Liver, Elasticity, Attenuation and Dispersion) study, an international multicenter study aiming to evaluate quantitative ultrasound imaging tools against liver biopsy (the current clinical gold standard), available on the Aplio Liver Package for the assessment of Steatosis, Fibrosis, and Inflammation in the clinical environment.
  • The development of non-invasive assessment and staging tools for liver disease has the potential to reach into the community to provide quantitative health data that supports the management of liver disease, regardless of population location.
  • “This is an exciting step in the validation of non-invasive tools for the assessment and management of liver disease,” said representative researcher, Prof.

Canon Medical announced today its support for the iLEAD (innovative Liver, Elasticity, Attenuation and Dispersion) study, an international multicenter study aiming to evaluate quantitative ultrasound imaging tools against liver biopsy (the current clinical gold standard), available on the Aplio Liver Package for the assessment of Steatosis, Fibrosis, and Inflammation in the clinical environment.

This Multicenter study is focusing on the assessment of NASH (Non-Alcoholic SteatoHepatitis) using non-invasive innovative ultrasound liver imaging techniques against the current gold standard of liver biopsy. Researchers from China, Japan, South Korea, USA and Europe, aim to recruit over 200 patients for the study and to compare their results. Researchers believe that the non-invasive ultrasound diagnostics can provide a faster, safer, and more readily available assessment of NASH that may benefit patients by earlier detection, treatment and follow up.

The Aplio system now boasts three separate technologies and an integrated multi-parametric reporting capability that brings quantifiable imaging of the liver into the daily routine.

  • Shear Wave Elastography (SWE)
  • Shear Wave Dispersion (SWD)
  • Attenuation Imaging (ATI)

These tools include safe, non-invasive, robust, and reproducible quantitative assessment of Liver.

The global burden of liver disease, along with its significant individual, community and financial implications, has driven ultrasound development of non-invasive, safe tools. These can be utilized to diagnose and follow up patients at risk of steatosis, with implications for not only severe liver disease, cardiovascular disease and diabetes.

Aplio i-series, first launched in 2016, is widely used for premium performance abdominal imaging. The development of non-invasive assessment and staging tools for liver disease has the potential to reach into the community to provide quantitative health data that supports the management of liver disease, regardless of population location.

“This is an exciting step in the validation of non-invasive tools for the assessment and management of liver disease,” said representative researcher, Prof. Fuminori Moriyasu, Professor & Director, Center for Cancer Ablation Therapy, International University of Health and Welfare, Sanno Hospital, Tokyo, Japan.

“The liver tools provided by the Aplio result from over 50 years of technological development, knowledge and expertise, combined with strong collaboration with global clinical partners,” said Akihiro Sano, General Manager, Ultrasound, Canon Medical.

The Multicenter study is targeting RSNA 2022 to present its findings; with interim findings released as appropriate.

Aplio is a trademark of Canon Medical Systems Corporation.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Phase 1 Study Measuring Dosing Effects of LSD Completed: Results of Study Will Aid In Planning a Phase 2 Study

The study was conducted in partnership with University Hospital Basel's Liechti Lab.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

NuVision ICE Catheter: Positive Results From First-in-human Feasibility Study Reported At 2020 TCT Conference

"Initial clinical experience of the NuVision ICE Catheter supports safe and effective use with all primary and secondary safety and performance endpoints met and zero adverse events reported," commented Dr. Latib.

By using this website you agree to accept Medical Device News Magazine Privacy Policy